Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues    
Service $ 5,356 $ 60,254
Product 144,452 53,957
Total Revenues 149,808 114,211
Operating Expenses    
Research and development 4,905,678 3,590,053
General and administrative 2,581,703 2,602,152
Sales and marketing 1,707,457 1,598,983
Total Operating Expenses 9,194,838 7,791,188
Operating Loss (9,045,030) (7,676,977)
Other Income (Expenses)    
Grant income 165,795 0
Interest income 57,648 2
Interest expense (51,322) (41,032)
Total Other Income (Expenses) 172,121 (41,030)
Net Loss (8,872,909) (7,718,007)
Net Loss attributable to Non-Controlling Interest 93,361 83,977
Net Loss attributable to VolitionRx Stockholders (8,779,548) (7,634,030)
Other Comprehensive Loss    
Foreign currency translation adjustments (56,478) (117,904)
Net Comprehensive Loss $ (8,929,387) $ (7,835,911)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Stockholders $ (0.15) $ (0.14)
Weighted Average Shares Outstanding    
- Basic and Diluted 60,176,975 53,775,096